Answers are grounded in this paper and cite their sources.
The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with placebo. (Funded by AstraZeneca and Merck; SOLO1 ClinicalTrials.gov number, NCT01844986 .).
No takes yet. Share an insight, caveat, or question.
Moore et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: